Objective To explore the clinical efficacy and safety of Xiaozhang Yiliu Fang（ 消胀抑瘤方） combined with systemic or intraperitoneal chemotherapy in treating advanced gastric cancer-induced malignant ascites.Methods Seventy patients with advanced gastric cancer-induced malignant ascites and differentiated as liver constraint and spleen deficiency type were randomized into treatment group and control group with 35 cases in each group. The control group was administered Calcium levofolinate 100 mg/m

2

+ 5-fluorouracil 2. 0 g/m

2

+ Paclitaxel95 mg/m

2

（ intravenous infusion） + Paclitaxel 30 mg/m

2

（ intraperitoneal chemotherapy） biweekly therapy. In addition to the same chemotherapy

the treatment group also took Xiaozhang Yiliu Fang orally with one dose a day. Both groups were treated for 30 days. After treatment

the ascites changes and Chinese medicine syndrome changes were observed. During treatment

the drainage times and adverse reactions were recorded. Results For the ascites

the total effective rate in the treatment group was 62. 86%

and the stable rate was 85. 71%; those in the control group were respectively 51. 43% and 62. 86%. The stable rate in the treatment group was significantly higher than that in the control group（ P

<

0. 05）. The drainage frequency in the treatment was significantly lower than that in the control group（ P

<

0. 05）. So was the incidence rate of adverse reactions such as nausea

emesis

diarrhea

neutrophil decreasing and transaminases elevating（ P

<

0. 05）. The efficacy of improving the Chinese medicine syndrome in the treatment group was significantly better than that in the control group（ P

<

0. 05）. Conclusion Xiaozhang Yiliu Fang combined with systematic or intraperitoneal chemotherapy shows better effect than chemotherapy alone in treating gastric cancer-induced malignant ascites patients of liver constraint and spleen deficiency type. It could increase the stable rate in treating ascites

reduce the drainage times during treatment as well as relieving the chemotherapyinduced adverse reactions and improving Chinese medicine syndromes with good clinical safety.